Articles tagged with Respiratory Syncytial Virus
A study found that Nirsevimab was associated with a substantial reduction in respiratory syncytial virus-lower respiratory tract infection hospitalizations during the first year. It was not linked to reduced hospitalizations due to non-RSV infections or asthma, nor during the second year of follow-up.
A recent study found that human lung tissue contains a vast reservoir of tissue-resident memory T cells (T RM cells) capable of targeting a range of viruses, bacteria, and fungi. These cells reside only in the lungs and can live for years, providing a vital line of defense against severe respiratory infections.
Clesrovimab, a long-acting monoclonal antibody, demonstrates safety and efficacy in reducing severe respiratory syncytial virus (RSV) disease in high-risk infants over two RSV seasons. The study supports the use of clesrovimab in children at increased risk for severe RSV disease during their second season.
A new study by researchers at UCL and GOSH found that the infant airway itself ramps up the immune response, causing damage to lungs. The team tested antiviral drugs, finding that RSV604 calmed the overactive immune response, reducing inflammation levels.
A study finds that maternal RSV prefusion F vaccination protects against RSV-associated acute respiratory illness and lowers hospitalization rates among infants under 1 year. The findings support the effectiveness of this vaccine in preventing severe respiratory illnesses.
A new study presents dual immunization against respiratory syncytial virus (RSV) using RSVpreF and nirsevimab, showing reduced hospitalizations among infants in France. The study found that this combined approach demonstrates potential for enhanced RSV prevention and protection
A new study found that infants receiving maternal RSV vaccination or Nirsevimab after birth had significantly lower RSV infection rates and fewer severe complications. The study showed a high uptake of the vaccines among pregnant patients and newborns, leading to declining rates of RSV-related illnesses.
The American College of Physicians advises all adults aged 75 or older to receive a protein subunit Respiratory Syncytial Virus (RSV) vaccine, reducing the risk of severe illness and hospitalization. Adults aged 60-74 with comorbid conditions may also consider receiving the vaccine. The benefits outweigh the harms in this age group.
A recent study published in Science Translational Medicine found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications. Infants infected with RSV often develop severe symptoms due to low levels of systemic inflammation and a poorly coordinated early immune response.
A recent study found that respiratory syncytial virus (RSV) hospitalizations are associated with a higher risk of cardiorespiratory events, with some conditions experiencing elevated risks up to 180 days after admission. The findings highlight the importance of increasing RSV immunization in adults to mitigate this risk.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
The CDC recommends RSV vaccination for pregnant women to protect their newborns, while a monoclonal antibody injection is also available for high-risk infants. Most experts agree that RSV immunizations should be recommended for these groups due to the severity of the illness they can cause.
A recent study found that the RSVpreF vaccine does not pose a significant risk to pregnant women, providing reassurance for those who wish to be vaccinated. The interim report presents data from a large cohort of pregnancies with vaccine-seeking behavior, and results suggest no notable adverse effects.
Recent advances in maternal vaccines and long-acting monoclonal antibodies have broadened the scope of RSV prevention, reducing disease burden and improving infant survival outcomes. The expert panel concludes that both strategies demonstrate strong benefit–risk profiles when used appropriately.
A population-based surveillance study found both maternal RSV vaccine and nirsevimab effective in protecting infants from RSV hospitalizations. The studies results show that these products reduced RSV-associated hospitalization rates in newborns and infants under 11 months by up to half compared to previous seasons.
A study published in JAMA found that nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes compared to maternal vaccination with the RSVpreF vaccine. These findings suggest a potential benefit for passive infant immunization with nirsevimab in reducing RSV-related complications.
A new study found that adults hospitalized with RSV often struggle with breathlessness, reduced ability to perform everyday activities, and lower quality of life six to 12 months after their hospitalization. The study also showed that younger adults can experience serious RSV infections requiring hospitalization, similar to older adults.
A new study suggests that expanding seasonal immunization access could minimize off-season RSV epidemics, with higher rates of hospitalizations in urban areas compared to rural communities. Providing year-round access to RSV immunization would be more risk-averse and minimize risks of large seasonal outbreaks.
A European study found that long-acting monoclonal antibody immunisation effectively prevented hospitalisation due to RSV infection among children under two years old. The overall immunisation effectiveness was 79%, with a decline in protection over time, highlighting the need for ongoing monitoring.
In response to rising RSV cases, ECDC advises policymakers and public health authorities on effective ways to mitigate the impact of RSV disease in infants. Immunisation interventions, including long-acting monoclonal antibodies and maternal vaccines, can prevent severe illness and hospitalization.
A new Cochrane review finds RSV vaccines reduce the risk of infection in vulnerable groups, including older adults and infants. Vaccination also significantly reduces severe disease and hospitalization rates.
New Cochrane review finds RSV vaccines protect against severe lung infections in high-risk groups. Vaccination with RSV prefusion vaccines reduces lower respiratory tract disease by 77% in older adults, while pregnant people's children benefit from reduced hospitalization risk by 54%.
A study published in JAMA found that one shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons. The vaccine reduced the risk of hospitalization by 58% overall, with a higher reduction seen in the first year after vaccination.
A retrospective study found that older adults hospitalized with RSV experienced significantly longer hospital stays, transfers to intensive care, and 30-day mortality compared to patients with other conditions. Additionally, RSV hospitalization was associated with higher rates of heart failure and atrial fibrillation post-discharge.
Researchers found a significant link between vaccination of pregnant women and a drop in newborns being admitted to hospital with a serious lung infection. The RSV vaccine offered a 72% reduction in hospital admissions, with mothers who received the jab before delivery having twice the protective effect.
A study found that adults hospitalized for RSV had significantly higher odds of cardiac events compared to those with COVID-19 or influenza. The findings suggest that preexisting cardiovascular risk patients should consider vaccination against respiratory viral infections.
Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic costs. The study found that the main sources of costs were repeated visits to primary care physicians and parents missing work to care for their sick children, with higher costs for infants under 1 year old.
The RSV protein subunit vaccine showed similar efficacy to clinical trials, with diminished immune response in immunocompromised patients. The vaccine was associated with a small increased risk of Guillain-Barré syndrome, but not immune thrombocytopenic purpura.
A major Danish nationwide cohort study found that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) experience significantly worse health outcomes, including a 2.7-fold higher risk of death within one year compared to the general population. RSV-ARI also leads to exacerbations of COPD and asthma, ...
Severe RSV disease among children is more likely those aged 2 or older with pulmonary or neurologic conditions. Younger children under 6 months and prematurity are high-risk factors for severe RSV in younger kids.
A cross-sectional study found that hospitalized adults with RSV vaccine eligibility were more likely to receive the vaccine. Sociodemographic differences in vaccine uptake occurred, suggesting appropriate prioritization of populations with increased risk.
A study found that RSV hospitalization rates increase progressively with age among older adults in Spain, with those over 85 years old facing the highest risk. Certain chronic conditions, such as blood cancer, COPD, and cardiovascular disease, also significantly increase the risk of hospitalization.
A cohort study found COVID-19 to be associated with more severe disease outcomes compared to influenza and RSV during the 2022-2023 season. Vaccination attenuated these differences in severity and long-term mortality rates.
Stephania Cormier and colleagues lead a Frontiers in Immunology research collaboration to explain RSV's complex interplay with host immune responses. The team identifies gaps in knowledge, hindering therapeutics and vaccines development.
Researchers found that older adults with weakened immunity developed fewer antibodies against RSV following vaccination compared to healthy individuals. The study suggests that adjuvant-enhanced vaccines could improve immune responses in immunocompromised people, warranting further investigation.
According to a new survey, over half of U.S. adults believe the RSV vaccine is effective in protecting infants from the virus, up from 42% last year. The rise in perceived effectiveness comes as several politicians have cast doubt on the vaccine's safety and efficacy.
Researchers provide comprehensive review of RSV's virology, clinical impact, and prevention strategies, emphasizing the need for effective vaccines to mitigate this critical health need. The review highlights RSV's severe impact on infants, children, and older adults, as well as its potential effects on multiple organs and systems.
The study analyzed the high burden of RSV-associated acute respiratory illness among young children in the U.S. and found nirsevimab to be effective against severe cases, highlighting the potential for substantial public health impact through increased prevention coverage.
A cohort study of adults with outpatient RSV infections found that approximately 1 in 20 experienced all-cause hospitalization within 28 days. The results highlight the need for RSV prevention and treatment to address public health concerns.
A cross-sectional study found substantial burden of RSV-related hospitalizations, ICU admissions, and deaths in US adults. Increasing RSV vaccination among older adults has the potential to reduce these outcomes.
New RSV vaccines have been found to be highly effective in preventing severe respiratory illness and hospitalizations, with an 80% efficacy rate. However, vaccination rates remain low, especially among older adults, highlighting the need for better understanding of risk factors and improved healthcare provider education.
A new study found distinct changes in children with severe cases of RSV, including elevated NK cells in the airways and altered immunological function. This research may help identify new targets for future treatments.
Researchers at the University of Wisconsin-Madison have imaged the structure of RSV proteins, which are crucial for the virus's interaction with host cells. The images reveal that pairs of F proteins may be a key target for destabilizing the virus and preventing infection.
A cross-sectional study found significant increases in sudden unexpected infant death (SUID) and sudden infant death syndrome (SIDS) during the COVID-19 pandemic. The rise in SUID rates was linked to off-season resurgences of infectious pathogens, with RSV rates closely approximating this shift.
A new study found that RSV vaccination programs targeting older adults with underlying health conditions are more likely to be cost-effective than general age-based strategies. Vaccinating people aged 70 years and older with chronic medical conditions is likely to be cost-effective based on commonly used cost-effectiveness thresholds.
A study found that RSV vaccination significantly reduced hospitalization risk among adults 60+ in the US, offering protection against severe RSV disease. The vaccine demonstrated effectiveness in high-risk populations, including those over 75 and with immunocompromising conditions.
Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.
A new personalized risk prediction tool may help identify newborns at highest risk for developing serious Respiratory Syncytial Virus (RSV) lower respiratory tract infection. The tool, developed using readily available birth and postnatal data, has good predictive accuracy and internal validation.
A new tool helps prioritize infants most at risk for severe RSV illness, allowing for targeted preventive medication with long-acting nirsevimab. The tool has good predictive accuracy and internal validation, indicating a potential game-changer in RSV prevention among high-risk infants.
Over five RSV seasons, researchers found that nearly one-quarter of hospitalized adults aged 50+ experienced an acute cardiac event, mostly heart failure. The risk of severe outcomes was nearly twice as high in patients with cardiac events compared to those without.
Researchers found RSV was less common but similar in severity to COVID-19 and influenza among unvaccinated patients. Among vaccinated patients, RSV disease was more severe than both COVID-19 and influenza for serious outcomes.
A study by Texas A&M University found that only 9% of older Americans had been vaccinated against RSV prior to this fall and winter. The study also revealed that men were more likely to be vaccinated than women, and those who were vaccinated had higher levels of concern about the disease.
Early data from Luxembourg's national immunisation campaign against severe respiratory syncytial virus (RSV) in 2023 showed a decline in hospitalisations, especially among infants under six months old. The authors attributed this to the administration of a monoclonal antibody, nirsevimab, shortly after birth. Additionally, the mean age...
Despite pandemic disruptions, emergency visits, hospital admissions, and intensive care unit stays were lower for children. However, there were delays in new diagnoses of cancer and diabetes, and an increase in diabetic ketoacidosis among children with diabetes. Researchers urge education campaigns to improve future pandemic preparedness.
A new study reveals that Respiratory Syncytial Virus (RSV) can infect nerve cells, trigger inflammation, and cause nerve damage. RSV was previously thought to only infect the respiratory tract, but this finding suggests a potential link between the virus and neurological symptoms in children.
A new study finds that most US parents intend to vaccinate their infants and young children against COVID-19, influenza, and respiratory syncytial virus (RSV), with 40% planning to vaccinate against COVID-19. The study also highlights the growing concern of vaccine hesitancy and its potential impact on public health.
The European Union has approved vaccines for pregnant women and monoclonal antibodies to prevent respiratory syncytial virus (RSV) among young children. New sequencing tools have also been developed to track the genetic diversity of RSV and inform vaccine effectiveness and treatment strategies.
A new study has identified 16 major risk factors for severe RSV infection in children under one year of age. The researchers created a clinical prediction model that performed well in both Finland and Sweden, highlighting the need for targeted prevention measures for high-risk infants.
A substantial burden of RSV-associated hospitalizations was found in Canadian pediatric hospitals, especially among infants under six months. The study suggests that preventive strategies for these young infants could lead to decreased RSV disease burden in children.
A new study using wastewater surveillance has predicted the start of the annual RSV season 12 days early, allowing hospitals to prepare and allocate resources effectively. The study used real-time wastewater measurements to forecast the surge in pediatric RSV cases, providing a population-level early warning signal for the community.